Scientific Reports,
Journal Year:
2023,
Volume and Issue:
13(1)
Published: Nov. 13, 2023
Risks
of
atherosclerotic
events
substantially
vary
even
among
patients
with
familial
hypercholesterolemia
(FH)
extremely
high
risk
based
on
life-long
exposure
to
low-density
lipoprotein
cholesterol
levels.
This
study
aimed
examine
the
impact
severe
FH
status
defined
by
International
Atherosclerosis
Society
(IAS).
Data
(N
=
1050,
male
490)
who
were
admitted
Kanazawa
University
Hospital
between
2000
and
2020
followed
up
retrospectively
reviewed.
The
number
major
adverse
cardiac
(MACEs),
including
mortality
associated
cardiovascular
disease,
acute
coronary
syndrome,
ischemic
heart
disease
requiring
revascularization
per
1000
person-years,
was
calculated.
Hazard
ratio
also
calculated
using
Cox
proportional
model.
Overall,
545
(51.9%)
had
FH.
median
follow-up
duration
12.6
years.
In
total,
171
MACEs
recorded
during
period.
Severe
significantly
MACE
(hazard
6.48,
95%
confidence
interval
2.56-10.40,
P
1.2
×
10-5).
event
rates
person-years
in
primary
prevention
group
non-severe
FH,
0.0
15.6,
respectively.
secondary
2.0
32.3,
Patients
exhibited
higher
risks
settings.
simple
criterion
provides
useful
information
for
identifying
may
need
further
management.
JACC Case Reports,
Journal Year:
2024,
Volume and Issue:
29(12), P. 102367 - 102367
Published: May 12, 2024
We
present
a
young
boy
with
diagnosis
of
homozygous
familial
hypercholesterolemia
who
presented
statin
and
ezetimibe
resistance.
The
patient
received
lipoprotein
apheresis
at
6
years
age.
His
low-density
cholesterol
levels
significantly
were
reduced
by
adding
lomitapide
evinacumab,
his
carotid
plaque
started
to
regress.
Nutrients,
Journal Year:
2024,
Volume and Issue:
16(17), P. 2927 - 2927
Published: Sept. 1, 2024
Dyslipidemia
is
a
significant
risk
factor
for
atherosclerotic
cardiovascular
disease
(ASCVD).
During
pregnancy,
physiological
changes
elevate
cholesterol
and
triglyceride
levels
to
support
fetal
development,
which
can
exacerbate
pre-existing
conditions
lead
complications
such
as
pre-eclampsia,
gestational
diabetes,
increased
ASCVD
both
mother
child.
Effective
management
strategies
are
necessary,
especially
pregnant
women
with
inherited
forms
of
dyslipidemia
(i.e.,
familial
hypertriglyceridemia,
hyperchylomicronemia),
where
personalized
dietary
adjustments
crucial
successful
pregnancy
outcomes.
Pharmacological
interventions
lipoprotein
apheresis
may
be
necessary
severe
cases,
though
their
use
often
limited
by
factors
cost,
availability,
potential
risks.
Despite
the
promise
advanced
therapies,
widespread
application
remains
constrained
studies
high
costs.
Thus,
personalized,
multidisciplinary
approach
essential
optimizing
This
review
provides
comprehensive
overview
current
evidence-based
practices
managing
during
emphasizing
balance
maternal
health.
Additionally,
it
discusses
in
lipid
metabolism
implications,
particularly
dyslipidemia.
Cardiogenetics,
Journal Year:
2025,
Volume and Issue:
15(1), P. 1 - 1
Published: Jan. 1, 2025
Introduction:
Familial
hypercholesterolemia
(FH)
is
a
genetic
disorder
that
remains
underdiagnosed
and
undertreated.
It
characterized
by
high
levels
of
low-density
lipoprotein
cholesterol
(LDL-C),
which
leads
to
an
increased
cardiovascular
disease
risk.
Pharmacotherapy
FH
based
on
high-dose
statin
therapy,
often
combined
with
ezetimibe
proprotein
convertase
subtilisin/kexin
9
inhibitors.
The
dietary
approach
important
supportive
part
management.
Methods:
This
review
aimed
present
the
available
evidence
strategies
in
patients.
analyzed
aspects
included
macronutrients
such
as
fat
carbohydrate
intake,
well
role
fiber,
nutraceuticals
(omega-3,
beta-glucan,
phytosterols,
red
yeast
fermented
rice
extract),
overall
models.
Results
Conclusions:
Based
data,
Mediterranean
diet
model
advised
prevention,
including
patients
FH.
Regarding
detailed
recommendations,
current
state
knowledge
indicates
saturated
fatty
acids
intake
limitation
strategy.
Supplementation
phytosterols
fiber
can
be
also
helpful
Lipids in Health and Disease,
Journal Year:
2025,
Volume and Issue:
24(1)
Published: March 27, 2025
Familial
hypercholesterolemia
(FH)
significantly
amplifies
the
risk
of
developing
atherosclerotic
cardiovascular
disease
(ASCVD).
This
study
investigated
prevalence
and
clinical
characteristics
FH
in
a
hypertensive
rural
population.
In
China
H-type
Hypertension
Registry
Study,
prospective
observational
cohort
with
4-year
follow-up,
14,234
participants
from
areas
were
enrolled
2018,
onsite
exams
conducted
2022.
was
identified
using
Chinese-modified
Dutch
Lipid
Clinic
Network
criteria.
Among
10,900
patients
hypertension,
5,675
(52.1%)
women,
median
age
65
years,
blood
pressure
146/89
mmHg,
629
(5.8%)
had
previous
coronary
heart
(CHD),
4,726
(43.4%)
smokers.
cohort,
78
(0.72%)
met
C-DLCN
criteria
for
probable
or
definite
FH.
The
rate
lipid-lowering
therapy
(LLT)
usage
reached
35.9%.
After
follow-up
period
1,477
days,
total
658
deaths,
535
strokes,
309
(CVD)
events
observed.
At
baseline
subsequent
all
at
high
ultra/very
ASCVD.
During
greater
decrease
LDL-C
shown
(FH:
−
31%,
95%
CI
44.6%
to
–14.6%;
P
<
0.001)
than
without
(2%,
CI:
12.1%
17.4%);
however,
only
3.6%
them
achieved
recommended
targets
based
on
ASCVD
assessment.
risks
stroke
CVD
not
different
between
after
4
years
follow-up.
highlights
marked
gap
low
treatment
rates
populations
hypertension.
These
findings
suggest
need
improve
knowledge
regarding
treat
this
condition,
especially
when
associated
factors
are
present.
Russian Pediatric Journal,
Journal Year:
2025,
Volume and Issue:
28(2), P. 141 - 147
Published: April 29, 2025
Introduction.
Lipid
metabolism
disorders
play
a
key
role
in
the
development
of
cardiovascular
diseases
(CVD).
Hyperlipidemia,
which
occurred
childhood,
continues
to
progress
over
adulthood,
contributing
atherosclerosis.
The
lack
screening
for
lipid
profile,
clinical
manifestations
and
low
alertness
pediatricians,
lead
late
detection
this
pathology
minimize
possibility
using
set
preventive
measures.
aim
review
is
determine
features
diagnosis
an
algorithm
managing
children
with
dyslipidemia.
material
analysis
was
scientific
reports
selected
MedLine,
Google
Scholar,
PubMed
databases
from
1980
2025.
An
effective
way
diagnose
dyslipidemia
screening,
should
be
performed
at
age
9–11
years
17–21
years.
Dyslipidemia
diagnosed
when
changes
two
profiles
are
detected.
It
necessary
exclude
primary
hypercholesterolemia,
has
unfavourable
course.
Risk
factors
atherosclerosis
early
vascular
analyzed
management
tactics.
main
method
correcting
lifestyle
modification.
In
absence
effect,
statins
indicated,
drug
choice
all
developed
countries.
efficacy
safety
long-term
use
been
demonstrated.
Early
timely
initiation
treatment
hyperlipidemia
significant
reducing
risk
atherosclerotic
old
age.
